218 related articles for article (PubMed ID: 22229970)
21. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.
Okeley NM; Alley SC; Senter PD
Hematol Oncol Clin North Am; 2014 Feb; 28(1):13-25. PubMed ID: 24287064
[TBL] [Abstract][Full Text] [Related]
22. The next generation of antibody drug conjugates.
Mack F; Ritchie M; Sapra P
Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608
[TBL] [Abstract][Full Text] [Related]
23. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
Moulder SL
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S30-40. PubMed ID: 20805063
[TBL] [Abstract][Full Text] [Related]
24. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
25. Investigational antibody drug conjugates for solid tumors.
Sapra P; Hooper AT; O'Donnell CJ; Gerber HP
Expert Opin Investig Drugs; 2011 Aug; 20(8):1131-49. PubMed ID: 21599617
[TBL] [Abstract][Full Text] [Related]
26. Antibody-drug conjugates in cancer therapy.
Sievers EL; Senter PD
Annu Rev Med; 2013; 64():15-29. PubMed ID: 23043493
[TBL] [Abstract][Full Text] [Related]
27. [Indications for Herceptin in breast cancer treatment].
Beuzeboc P
Gynecol Obstet Fertil; 2004 Feb; 32(2):164-72. PubMed ID: 15123142
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
Deng S; Lin Z; Li W
Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
[TBL] [Abstract][Full Text] [Related]
29. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Niculescu-Duvaz I
Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
[TBL] [Abstract][Full Text] [Related]
31. [An overview of antibody therapy against cancer].
Taniguchi H; Imai K
Nihon Rinsho; 2012 Dec; 70(12):2087-92. PubMed ID: 23259378
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
33. Abagovomab for ovarian cancer.
Pfisterer J; Harter P; Simonelli C; Peters M; Berek J; Sabbatini P; du Bois A
Expert Opin Biol Ther; 2011 Mar; 11(3):395-403. PubMed ID: 21241213
[TBL] [Abstract][Full Text] [Related]
34. Antibody-drug conjugates in triple negative breast cancer.
Tray N; Adams S; Esteva FJ
Future Oncol; 2018 Oct; 14(25):2651-2661. PubMed ID: 30175620
[TBL] [Abstract][Full Text] [Related]
35. Challenges in the development and manufacturing of antibody-drug conjugates.
Ducry L
Methods Mol Biol; 2012; 899():489-97. PubMed ID: 22735971
[TBL] [Abstract][Full Text] [Related]
36. Advances in the approach to novel drug clinical development for breast cancer.
Ferrario C; Batist G
Expert Opin Drug Discov; 2014 Jun; 9(6):647-68. PubMed ID: 24758225
[TBL] [Abstract][Full Text] [Related]
37. Antibody-targeted drugs for the therapy of cancer.
Pietersz GA; Krauer K
J Drug Target; 1994; 2(3):183-215. PubMed ID: 7812691
[TBL] [Abstract][Full Text] [Related]
38. Treatment of metastatic breast cancer: looking towards the future.
Amar S; Roy V; Perez EA
Breast Cancer Res Treat; 2009 Apr; 114(3):413-22. PubMed ID: 18465221
[TBL] [Abstract][Full Text] [Related]
39. Herceptin and breast cancer: an overview for surgeons.
Patani N; Mokbel K
Surg Oncol; 2010 Mar; 19(1):e11-21. PubMed ID: 19097883
[TBL] [Abstract][Full Text] [Related]
40. [Antibody-drug conjugates: a new therapeutic class?].
Chofflon I; Dietrich PY; Thang NN
Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]